-
Impressive pipeline, good news, strong partners. It smells like buyout.
$BLUE$CELG#Medigene pic.twitter.com/bI8S30Na9x
-
#Medigene 's#TCR#CancerTherapy Can Begin Phase I/II Trials https://labiotech.eu/t-cell-receptor-therapy-medigene/ … via@labiotech_eu -
#Medigene in for up to $1.5 billion under broader pact with Bluebird Bio https://www.pharmacompass.com/radio-compass-news/america/medigene-in-for-up-to-1-5-billion-under-broader-pact-with-bluebird-bio#.Wvu2CvfkiIY.twitter … -
Chart-Bargain-Trade: Medigene The german Medigene is also a good Trader-Stock with big Return-Potential and it looks today like the perfect Buying-Point at the 200-Days-Line.
#stocks#shares#trading#investing#StockCharts#Aktien#Börse#Medigene pic.twitter.com/SpcHEWkjdB
-
Read this new eBook full of insight into cell therapy. Topics discussed include the commercial experience of cell and gene therapies from manufacturing and patient experiences to payment models and reimbursements. http://bit.ly/2MsqcUk
#Celltherapy#Medigene#PharmaIntelligencepic.twitter.com/KWNfTkpYUc
-
Listen in to RXi's recent webcast presentation to learn about our strategy to tackle different
#immune escape mechanisms to treat solid#tumors and view data from our collaborations with#CCIT,#Medigene and#GustaveRoussy#ImmunoOncology http://ow.ly/XRL930lJc1d pic.twitter.com/Ubbp7hvo6g
-
$MDG1k.DE
#MEDIGENE MEDIGENE: EHA 2019: ‘FAST-DC’ vaccine interim clinical results | | EUR16.7 (+125%): MEDIGENE - | EUR16.7 (+125%) EHA 2019: ‘FAST-DC’ vaccine interim clinical results FAST-DC vaccine phase I/II clinical trial FAST-DC vaccine… http://dlvr.it/R6sm7V pic.twitter.com/SCWcUnguqg
-
Medigene gets clinical trial approval for its innovative T cell receptor therapy to treat AML and other Hematological malignancies.
#medigene#germany#TCRtherapy#clinicaltrial#innovative#medigene#AML#MDShttps://www.fiercebiotech.com/biotech/medigene-gets-ok-for-first-trial-t-cell-receptor-therapy?mkt_tok=eyJpIjoiWm1VMU0yVmpOMkZqWmpOaSIsInQiOiIwOVwvNll2c3Zzd1UrN1JjVFh4ZDhrTlo1dXZ4Q1wvOVVPTVlRRGI1Q1YyODNBTU9reDh5TGdPR1pYdm1VK2V4SFRlNWlYdWFKVUd3TjFhT2d6NXFmd3IybVZaNEIwYzNMYUNMaVZIc0FybmhySVlMM3lTUXRSTFZKSTMwdFMxZVlHIn0%3D&mrkid=28187748 … -
#TCR the new#CAR? It is too early to answer this question. But$ADAP published promising results. Also the German company#Medigene plans clinical trials.#China is interested in this technology, too.$BLUE$GILDhttps://endpts.com/another-mega-startup-china-investors-back-tcr2s-125m-cash-round-to-fuel-a-preclinical-assault-on-solid-tumors/ … -
Check out the amazing programme for the Outsourcing in Clinical Trials DACH 2018 Conference! Hear from the likes of Jessica Cordes at
#Medigene AG, Olivier Goarnisson@Celgene Guido Koch#Topadur and many more http://ow.ly/AH5y30m8Dol pic.twitter.com/QDz8PMed3X
-
$MDG1
#Medigene AG Medigene - Positive momentum continued in H119: Medigene continued its positive momentum in H119 announcing a new partnership (Roivant/Cytovant), expansion of its internal pipeline (MDG1021), sale of a legacy asset (Veregen) and… http://dlvr.it/R9qzWF pic.twitter.com/GvNuQwoY7d
-
$MDG1
#Medigene AG ... ODDO BHF GERMAN MORNING NEWS – DETAILED COMMENTS 06.22.2018: NFON is a leading provider of public cloud telephony systems with a dense network of qualified resellers in Europe. Through its proprietary software as a service (SaaS)… http://dlvr.it/QY7PB6 pic.twitter.com/oJzATPTcnR
-
$MDG1
#Medigene AG Medigene - New assets, new partnerships: Medigene continues to position itself as a leader in cellular therapies by the expansion of both its internal pipeline (MDG1021) and external partnerships (Roivant/Cytovant). The company has… http://dlvr.it/R6tqxF pic.twitter.com/OGrLsa9GC3
-
Medigene, Bluebird Bio Collaboration on TCR Immunotherapy Extended
@pharmasalmanac#immunotherapy#bluebirdbio#Medigene https://lnkd.in/dx2z62P https://lnkd.in/dG5cb6B -
$MDGEF and IMO the winner will be#MEDIGENE DC with its fast 3 day TLR7/8-agonist maturation cocktail see recent#AACR18 presentations - production for completed AML trial http://www.abstractsonline.com/pp8/#!/4562/presentation/9718 … and results Oslo University prostate trial https://www.medigene.com/investors-media/press-releases/detail/article/clinical-data-for-dc-vaccine-in-prostate-cancer-iit-study-presented-by-oslo-university/ … pic.twitter.com/NMebKZ9plf
Prikaži ovu nit -
#Medigene: Excellent long-term chart setup, huge ascending triangle correction since 2015, today breakout with a gap long-term targets at 18, 22, 27 und 35 € (Medigene is a german biotech company)#aktien#equitiespic.twitter.com/qr9tOr2hem
-
#Medigene Highlights Its 'Im (#InducibleMedigene)-Tcr' Approach At CAR-TCR Summit 2019 In Boston, USA $MDG1 http://www.1stoncology.com/blog/medigene-highlights-its-im-inducible-medigene-tcr-approach-at-car-tcr-summit-2019-in-boston-usa1234539407 … -
#Medigene reported Positive Final 2-Year Topline Data in Completed#DCVaccine Phase I/II trial in#AML Patients $MDG1 http://www.1stoncology.com/blog/positive-final-2-year-topline-data-in-completed-dc-vaccine-phase-iii-trial-in-aml-patients1234552987 …
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.